Development of a bladder cancer drug-sensitivity platform based on cancer niche formation including immune cell components

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K09527
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56030:Urology-related
• Research Institution: Yamaguchi University
• Principal Investigator: Matsumoto Hiroaki 山口大学, 医学部附属病院, 講師 (60610673)
• Co-Investigator(Kenkyū-buntansha): 山本 義明 山口大学, 医学部, 特別医学研究員 (30593298) ; 平田 寛 山口大学, 医学部附属病院, 助教 (40781307) ; 清木 誠 山口大学, 大学院医学系研究科, 教授 (50226619) ; 松山 豪泰 山口大学, 大学院医学系研究科, 教授(特命) (70209667)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 膀胱癌 / 癌オルガノイド / 癌微小環境 / 3次元培養 / 薬剤感受性

Outline of Final Research Achievements

In collaboration with Tatsuya Usui, specially-appointed lecturer at Tokyo University of Agriculture and Technology, exfoliated cells were collected from bladder wash urine of bladder cancer patients, culture conditions were set, 3D culture was performed, and patient-derived bladder cancer organoids were created. 2.5D culture method reported by Usui et al (Scientific Reports. 2020, 10:9393) was used to create a transferrable strains were created. Co-culture models were also created by introducing GFP into bladder cancer cell lines (T24, TCCSUP, 5637, RT4 and SCaBER) and RFP into human immortalised cancer-associated fibroblasts.

Free Research Field

尿路悪性腫瘍

Academic Significance and Societal Importance of the Research Achievements

患者検体よりの膀胱癌オルガノイド作成により、従来の平面培養での細胞株樹立と異なりより生体内でのがんの微小環境に沿った薬物感受性やシグナル伝達経路の解明に貢献できるものと思われ、実験動物を使用せずによりハイスループットな、かつテーラーメード医療の基礎的技術となる可能性が示唆され、新たな膀胱癌治療ターゲットの創出に役立つものと思われる。